MUFG Securities EMEA plc trimmed its stake in Accuray Incorporated (NASDAQ:ARAY) by 24.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 162,520 shares of the medical equipment provider’s stock after selling 53,709 shares during the period. MUFG Securities EMEA plc’s holdings in Accuray were worth $629,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of ARAY. Dimensional Fund Advisors LP increased its stake in shares of Accuray by 3.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,321,330 shares of the medical equipment provider’s stock worth $7,916,000 after purchasing an additional 78,330 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of Accuray by 1,515.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 19,099 shares of the medical equipment provider’s stock worth $91,000 after purchasing an additional 17,917 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Accuray by 162.0% in the 1st quarter. Bank of Montreal Can now owns 32,118 shares of the medical equipment provider’s stock worth $153,000 after purchasing an additional 19,858 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Accuray in the 1st quarter worth $49,000. Finally, Candriam Luxembourg S.C.A. increased its stake in shares of Accuray by 163.3% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 218,191 shares of the medical equipment provider’s stock worth $1,041,000 after purchasing an additional 135,338 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Several equities research analysts have recently commented on ARAY shares. BidaskClub upgraded Accuray from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Royal Bank of Canada set a $4.00 price objective on Accuray and gave the stock a “hold” rating in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the company. The company has an average rating of “Hold” and an average target price of $4.47.

Shares of NASDAQ:ARAY remained flat at $$3.04 during midday trading on Friday. The stock had a trading volume of 20,186 shares, compared to its average volume of 755,402. The firm has a market cap of $269.89 million, a P/E ratio of -20.27 and a beta of 1.96. The company has a debt-to-equity ratio of 3.21, a quick ratio of 1.16 and a current ratio of 1.79. The business has a 50-day simple moving average of $3.23 and a two-hundred day simple moving average of $3.95. Accuray Incorporated has a 52-week low of $2.35 and a 52-week high of $5.40.

Accuray (NASDAQ:ARAY) last issued its earnings results on Thursday, August 15th. The medical equipment provider reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.05). The firm had revenue of $117.42 million during the quarter, compared to the consensus estimate of $116.09 million. Accuray had a negative return on equity of 26.69% and a negative net margin of 3.92%. During the same period in the prior year, the company posted ($0.01) EPS. On average, equities analysts expect that Accuray Incorporated will post -0.14 earnings per share for the current year.

In related news, CEO Joshua Levine sold 56,426 shares of the company’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $3.75, for a total value of $211,597.50. Following the completion of the transaction, the chief executive officer now owns 977,167 shares of the company’s stock, valued at approximately $3,664,376.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph E. Whitters bought 12,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average cost of $2.62 per share, with a total value of $32,750.00. Following the acquisition, the director now directly owns 116,780 shares in the company, valued at approximately $305,963.60. The disclosure for this purchase can be found here. Corporate insiders own 3.40% of the company’s stock.

Accuray Profile

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Recommended Story: Why is cost of goods sold important?

Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.